CRYSTALLINE PHARMACEUTICALLY ACTIVE INGREDIENTS

The present invention is related to crystalline forms of rosuvastatin zinc (2:1) salt. The polymorphs are suitable for use as pharmaceutically active ingredients in the treatment of the diseases of the lipid metabolism including hypercholesterolemia, hyperlipidemia, dyslipidemia or atherosclerosis.

Saved in:
Bibliographic Details
Main Authors HAMORI CSABA, KOVANYINE LAX GYORGYI, JURAK FERENC, SIPOS EVA, MEZOVARI MONIKA, HAVASI BALAZS, FODORNE KOCSMAR KRISZTINA, VOLK BALAZS, RUNGE ZSOLT, LUKACS GYULA, MARKOVITS IMRE, KATAINE FADGYAS KATALIN
Format Patent
LanguageEnglish
Published 30.07.2014
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention is related to crystalline forms of rosuvastatin zinc (2:1) salt. The polymorphs are suitable for use as pharmaceutically active ingredients in the treatment of the diseases of the lipid metabolism including hypercholesterolemia, hyperlipidemia, dyslipidemia or atherosclerosis.
Bibliography:Application Number: ZA20130003371